ER、PRL、HER-2、VEGF、E-cadherin在乳腺浸润性导管癌中的表达分析

Expression of ER, PRL, HER-2, VEGF and E-cadherin in invasive ductal carcinoma of breast

目的探讨、雌激素受体(ER)、催乳素(PRL)、人表皮生长因子受体-2(HER-2)、血管内皮生长因子(VEGF)和粘附分子(E-cadherin)在乳腺浸润性导管癌组织中的表达情况。方法应用免疫组织化学链霉菌抗生物蛋白-过氧化物酶染色法对55例乳腺浸润性导管癌的ER、PRL、HER-2、VEGF和E-cadherin分别进行检测。结果 ER、PRL、HER-2、VEGF和E-cadherin在55例乳腺浸润性导管癌组织中的阳性表达率分别为61.82%、58.18%、38.18%、36.36%和30.90%;55例乳腺浸润性导管癌发生淋巴结转移21例(38.18%),发生淋巴结转移的病例组中ER、PRL、HER-2、VEGF、E-cadherin的阳性表达率分别为66.67%、71.42%、42.86%、66.67%和45.00%。其中VEGF的表达在淋巴结转移组明显高于非转移组,差异有统计学意义(χ2=13.48,P<0.05)。乳腺癌中HER-2的表达与PRL呈负相关(r=-0.87,P<0.05),ER和PRL呈明显正相关(r=0.55,P<0.05)。结论 ER、PRL、HER-2、VEGF、E-cadherin与乳腺浸润性导管癌的发生和发展密切相关,可用来指导临床用药和判断预后。

Objective To explore the expression and analyze their relationship of HER-2, PRL, ER, VEGF and E-cadherin in invasive ductal carcinoma of breast. Methods The expression of ER, PRL, HER-2, VEGF and Ecadherin were evaluated by immunohistochemistry （SP method） in 55 cases with invasive ductal carcinoma of breast. Results The positive rates of ER, PRL, HER-2, VEGF and E-cadherin in 55 cases with invasive ductal carcinoma of breast were 61.82%, 58.18%, 38.18%, 36.36% and 30.90% respectively. The positive hyper-expression rates of ER, PRL, HER-2, VEGF and E-cadherin were 66.76%, 71.42%, 42.86%, 66.67% and 45.00% respectively in breast cancer cases with lymph node metastasis. The expression of VEGF in lymph node metastasis group was significantly higher than that of the non-transfer group （χ2=13.48,P0.05）. HER-2 expression and PRL expression was negatively correlated （r =0.87, P 0.05）, while ER and PRL was positive correlated （r = 0.55, P 0.05）. Conclusions ER, PRL, HER-2, VEGF, E-cadherin can be used to guide clinical treatment and diagnosis in patients with invasive ductal carcinoma of breast.